Anuh Pharma Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹185 Cr −0.5% YoYSee revenue, profit and what management said. You are viewing Q1 FY23.
AP

Anuh Pharma Ltd

Q1 FY23Pharmaceuticals & Biotechnology

Anuh Pharma Q1 FY23 earnings call: Revenue & Margins

Q1 FY23 investor presentation: what the company reported on revenue, margins and capex.

Based on Anuh Pharma Ltd's Q1 FY23 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹91
Market cap₹937 Cr
P/E21.2

The short version

Q1 FY23 Operating Revenue: Rs. 116.38 Cr, down 1% YoY from Rs. 117.27 Cr in Q1 FY22 (Page 14, 13). Q1 FY23 EBITDA: Rs. 12.14 Cr, up 18% YoY (Q1 FY22: Rs. 10.28 Cr).

From Anuh Pharma Ltd's Q1 FY23 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q1 FY23 Operating Revenue: Rs. 116.38 Cr, down 1% YoY from Rs. 117.27 Cr in Q1 FY22 (Page 14, 13)
  • Domestic Sales Contribution: 61% in Q1 FY23 (up from 49% in Q1 FY22) (Page 9)
  • Export Sales Contribution: 39% in Q1 FY23 (down from 51% in Q1 FY22) (Page 9)
  • Export sales increased by 50% compared to Q1 FY22 (Page 6)
  • Outlook:
  • Expect upswing in demand from next quarters, driven by anti-malarial, corticosteroids, diabetic, and expectorant segments (Page 6)

2 more points from Anuh Pharma Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Anuh Pharma Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

- Enhanced manufacturing capacity at L&L site for corticosteroids increased to 12 MTPA. - New plant in Tarapur (capacity 1500 MT) commenced in 2019; used for higher market share in Sulfadoxine, Ambroxol HCl, Gliclazide, and new product launches. Summary: The presentation describes a completed capacity expansion at Tarapur (1500 MT, started 2019), corticosteroids capacity enhancement to 12 MTPA at L&L site, and ongoing efficiency and R&D investments without stated capex amounts or timelines.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Anuh Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Anuh Pharma Ltd said on order book & pipeline — free account, 30 seconds.

Anuh Pharma Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹185 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Anuh Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Anuh Pharma Ltd Q1 FY23 results?

Q1 FY23 Operating Revenue: Rs. 116.38 Cr, down 1% YoY from Rs. 117.27 Cr in Q1 FY22 (Page 14, 13). Q1 FY23 EBITDA: Rs. 12.14 Cr, up 18% YoY (Q1 FY22: Rs. 10.28 Cr).

What is Anuh Pharma Ltd share price analysis?

Anuh Pharma Ltd currently shows a neutral. The stock trades at a P/E of 21.2 with a market cap of ₹937 Cr. Investors should review the full earnings analysis for detailed insights.

Is Anuh Pharma Ltd planning capital expenditure?

Enhanced manufacturing capacity at L&L site for corticosteroids increased to 12 MTPA.

Keep Anuh Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.